---
title: "Bering Partners II Discloses Investment at CalciMedica with 6.9% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291602559.md"
description: "Bering Partners II disclosed a 6.9% stake in CalciMedica via a Schedule 13D filed on July 2, 2026. The fund acquired 1,450,267 units at $0.8033 each through a June 25 private placement, shifting its filing from 13G to 13D status. This move includes raising warrant ownership caps to 19.99%, indicating potential for further investment activity."
datetime: "2026-07-03T00:36:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291602559.md)
  - [en](https://longbridge.com/en/news/291602559.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291602559.md)
---

# Bering Partners II Discloses Investment at CalciMedica with 6.9% Stake

Bering Partners II, L.P. disclosed a 6.9% stake in CalciMedica, Inc. common stock. The Schedule 13D was filed on Jul. 02, 2026 after the fund bought 1,450,267 units in CalciMedica’s June 25 private placement. The move shifts their prior 13G to a 13D and follows an increase to a 19.99% warrant ownership cap, signaling room to act.

**Investor Intent**

Bering Partners II bought 1,450,267 units at $0.8033 per unit on June 25, receiving common shares now and rights to Series A and Series B warrants once stockholders approve them. The fund also holds a 2024 warrant that it kept active through Dec. 31, 2026, and on Jul. 2 it raised that warrant’s ownership cap to 19.99%.

Both the new Series A and Series B warrants include a similar limit: “may not be exercised if the aggregate number of shares…would exceed…19.99%.” The fund says it holds the position for investment and may buy more or sell shares as conditions evolve.

**Investor's Background**

Bering Partners II, L.P. is a Delaware limited partnership and venture capital investment entity managed by Bering Partners II GP, L.L.C. The firm is led by managing members Evgeny Zaytsev and Philip Sawyer and invests in companies for capital appreciation. Zaytsev serves on CalciMedica’s board, providing board-level visibility into the business.

Original SEC Filing: CalciMedica, Inc. \[ CALC \] - SCHEDULE 13D - Jul. 02, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CALC.US](https://longbridge.com/en/quote/CALC.US.md)

## Related News & Research

- [CalciMedica Q2 net loss widens](https://longbridge.com/en/news/295526807.md)
- [CalciMedica announces annual shareholder meeting](https://longbridge.com/en/news/292531076.md)
- [CALC sets board meeting to review interim results, weigh dividend](https://longbridge.com/en/news/295385710.md)
- [CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates | CALC Stock News](https://longbridge.com/en/news/286084518.md)
- [CalciMedica says FDA review clears Auxora dosing to continue in Phase 2 KOURAGE AKI trial](https://longbridge.com/en/news/290683015.md)